Shanghai Fosun Pharmaceutical (02196): The drug registration application for the new indication of Lenvatinib tablets has been approved.
Fosun Pharma (02196) announced that its subsidiary Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. recently received approval from the National Medical Products Administration for the registration application of the drug Luweimeitini tablets (trade name: Fomai Ning; project code: FCN-159) for a new indication. The newly approved indication is for children and adolescents aged 2 and above with refractory or recurrent Langerhans cell histiocytosis (LCH) after systemic therapy.
Shanghai Fosun Pharmaceutical (02196) announced that its controlling subsidiary Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. has recently received approval from the National Medical Products Administration for a new indication for its drug Lenvatinib Mesylate Tablets (brand name: Fumainin; project code: FCN-159). The newly approved indication is for the treatment of Langerhans cell histiocytosis (LCH) in children and adolescents aged 2 and older who have relapsed or are refractory after systemic therapy.
Related Articles
REFIRE (02570) completes the conversion of 26.6106 million domestic shares into 26.6106 million H shares.
On June 15, KINDSTAR GLOBAL (09960) spent HKD 12,400 to buy back 12,500 shares.
Guangdong Jiangxi Wannianqing Cement (301111.SZ) shareholder intends to transfer 6% of the company's shares through inquiry.
REFIRE (02570) completes the conversion of 26.6106 million domestic shares into 26.6106 million H shares.
On June 15, KINDSTAR GLOBAL (09960) spent HKD 12,400 to buy back 12,500 shares.
Guangdong Jiangxi Wannianqing Cement (301111.SZ) shareholder intends to transfer 6% of the company's shares through inquiry.
RECOMMEND
